HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

Belizna C., Pregnolato F., Abad S., Alijotas-Reig J., Amital H., Amoura Z., ...More

AUTOIMMUNITY REVIEWS, vol.17, no.12, pp.1153-1168, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 17 Issue: 12
  • Publication Date: 2018
  • Doi Number: 10.1016/j.autrev.2018.05.012
  • Journal Name: AUTOIMMUNITY REVIEWS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1153-1168
  • Hacettepe University Affiliated: Yes

Abstract

The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3].